Nanostructured Cubosomes in a Thermoresponsive Depot System: An Alternative Approach for the Controlled Delivery of Docetaxel by Rarokar, Nilesh et al.
Research Article
Nanostructured Cubosomes in a Thermoresponsive Depot System:
An Alternative Approach for the Controlled Delivery of Docetaxel
Nilesh R. Rarokar,1 Suprit D. Saoji,1 Nishikant A. Raut,1 Jayashree B. Taksande,2
Pramod B. Khedekar,1 and Vivek S. Dave3,4
Received 28 June 2015; accepted 13 July 2015; published online 25 July 2015
Abstract. The aim of the present study was to develop and evaluate a thermoresponsive depot system
comprising of docetaxel-loaded cubosomes. The cubosomes were dispersed within a thermoreversible
gelling system for controlled drug delivery. The cubosome dispersion was prepared by dilution method,
followed by homogenization using glyceryl monooleate, ethanol and Pluronic® F127 in distilled water. The
cubosome dispersion was then incorporated into a gelling system prepared with Pluronic® F127 and
Pluronic® F68 in various ratios to formulate a thermoresponsive depot system. The thermoresponsive
depot formulations undergo a thermoreversible gelation process i.e., they exists as free flowing liquids at
room temperature, and transforms into gels at higher temperatures e.g., body temperature, to form a
stable depot in aqueous environment. The mean particle size of the cubosomes in the dispersion prepared
with Pluronic® F127, with and without the drug was found to be 170 and 280 nm, respectively. The
prepared thermoresponsive depot system was evaluated by assessing various parameters like time for
gelation, injectability, gel erosion, and in-vitro drug release. The drug-release studies of the cubosome
dispersion before incorporation into the gelling system revealed that a majority (∼97%) of the drug was
released within 12 h. This formulation also showed a short lag time (∼3 min). However, when incorpo-
rated into a thermoresponsive depot system, the formulation exhibited an initial burst release of ∼21%,
and released only ∼39% drug over a period of 12 h, thus indicating its potential as a controlled drug
delivery system.
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INTRODUCTION
Controlled drug delivery systems are typically designed
to optimize the drug release profiles. Polymers, surfactants,
and other such excipients are commonly employed in the
preparation of modern controlled drug delivery systems. Spe-
cific surfactant and polymer systems are known to form supra-
assemblies in situ and can be used to design systems for the
delivery of active pharmaceutical ingredients (APIs) (1–4).
These systems typically include liquid crystalline aggregates
such as liposomes and cubosomes, or cross-linked gel net-
works such as hydrogels etc. Incorporation of drugs into the
complex internal domains of these structures can facilitate a
diffusion-controlled release of the drug into the surrounding
external aqueous environment and may provide new ways to
modify pharmacokinetic profiles using lipid-based systems (5–
9). The success of these systems as controlled drug delivery
systems depends significantly on several formulation and pro-
cess variables. These factors include, but not limited to, the
drug-loading capacity, physical-chemical compatibility of the
drug and the vehicle, and the stability of the system (1).
Cubosomes have been described as bi-continuous cubic
phase liquid crystals consisting of two separate, continuous,
and non-intersecting hydrophilic regions divided by a lipid
bilayer (1). Cubosomes possess several properties that make
them amenable as potential carriers for drug delivery.
Cubosomes are nanoparticles (or more accurately nanostruc-
tured particles) that exist in a self-assembled liquid-crystalline
phase with a solid-like rheology. In recent years, there has
been a growing interest among researchers in exploring the
pharmaceutical applications of cubosomes and cubosome-
based systems. With the recent developments in the technol-
ogy, experience and expertise in the area of nano-pharmaceu-
ticals, cubosome-based systems are being actively pursued as
potential alternatives to now-common systems such as lipo-
somes and niosomes (10,11). Cubosomes are made up of a
binary system of monoolein and water, where the monoolein
acts as a precursor for lipid bilayer, which divides the hydro-
philic regions of cubic phases (10,12). This binary system can
self-assemble into thermodynamically stable bi-continuous,
cubic, liquid-crystalline phases (13).
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The feasibility of cubosomes as carriers for parenteral,
topical, and buccal delivery of drugs has been reported in the
literature (14–19). Formulations based on this technology
have been reported to have improved tolerance and drug
bioavailability (20). The parenteral administration route is
among the most common and efficient route for the delivery
of active drug substances with poor bioavailability and a nar-
row therapeutic index. However, parenteral route, along with
offering a rapid onset, is also associated with rapid decline in
systemic drug levels. An effective treatment often requires
maintaining systemic drug levels within the therapeutically
effective concentration range for an extended period. This
entails frequent injections, which may lead to patient discom-
fort and non-compliance.
Thus, a controlled drug delivery system comprising of
cubosome-based thermoreversible gel formulation may pro-
vide a possible solution to improve therapeutic efficiency. A
thermoreversible gel system essentially consists of a thermo-
gelling polymer, the aqueous solution of which is a liquid at or
below room temperature, and forms a gel at body temperature
(∼37°C) (21). Such systems have been suggested for the de-
livery of cells or biopharmaceuticals that are susceptible to
heat or organic solvents (21). Thermally induced gelling sys-
tems show thermoreversible sol/gel transitions and are char-
acterized by a lower critical solution temperature (22–25).
They are liquid at room temperature and produce a gel at
and above the lower critical solution temperature (22–25).
The incorporation of cubosomes into a thermoresponsive gel
should increase drug loading while, in all probability, yielding
a lower, more prolonged drug release compared with pure gel
(26). Therefore, a system containing both thermoresponsive
polymer and cubosome can combine the advantages of both
systems, the thermos-gelling properties of polymer and the
drug-carrying ability of the cubosome (26).
In the current study, the authors aimed to identify the
feasibility of developing such a system for controlling the
release of docetaxel. Docetaxel trihydrate (DTX) is an anti-
neoplastic agent which acts by blocking the cellular mitotic
and interphase functions (27,28). The anticancer activity of
DTX is dependent on its concentration and duration of expo-
sure. Although it is widely used in cancer chemotherapy,
several problems associated with its clinical use remain
unresolved. Due to its poor water-solubility, DXT is adminis-
tered by a continuous intravenous delivery along with lipo-
philic solvents. This formulation has limited stability and is
associated with significant vehicle-related toxicities (29–32).
The aim of our study was mainly divided into two com-
ponents. First, the development of a controlled-release formu-
lation of docetaxel consisting of cubosome as a carrier, loaded
within a thermoresponsive gel system. Secondly, optimizing
the concentrations of gel-forming agents that could potentially
meet the criteria for typical thermoresponsive gel-based drug
delivery systems. Figure 1 describes the general scheme of the
work flow, as followed.
MATERIALS AND METHODS
Materials
Docetaxel was obtained as a gift sample from Scino Phar-
maceutical Pvt., Taiwan. Glyceryl monooleate was obtained
from Otto Chemie., Mumbai (India). Pluronic® F127 (PF127)
obtained from Research Lab Fine Chem Industries, Mumbai
(India), and Pluronic® F68 (PF68) was obtained from
Himedia Laboratory Pvt. Ltd. HPMCK4Mwas obtained from
Raychem Lab. Chemical Pvt. Ltd., Chennai (India).
Carbopol® 934P and methylcellulose were obtained from
Loba Chemie Pvt. Ltd. Mumbai (India). Water was purified
on a Milli-Q system obtained from a Millipore® synergy sys-
tem (Millipore, Billerica, Massachusetts, USA). All other
chemicals used were of analytical grade.
Preparation of Cubosomes
Bulk cubic phases were prepared by modifying the
method suggested by Kojarunchitt et al. from a glyceryl
monooleate and Pluronic® F127 melt, with or without
drug (26). Briefly, glyceryl monooleate and Pluronic®
F127 (9:1 w/w) were melted at 60°C and mixed until
homogenous. The drug was loaded by first preparing a
solution in ethanol. This drug solution was then added to
a previously prepared homogeneous mixture of glyceryl
monooleate and Pluronic® F127. To this mixture, 5.0 mL
of ethanol was added as a hydrotropic solvent which helps
Fig. 1. Schematic representation of the development of thermoresponsive gel formulations containing docetaxel-loaded
cubosomes
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bind the hydrophilic and lipophilic phases, to form a bi-
continuous lipid bilayer.
To prepare the cubosome dispersion, the low-viscosity
homogenous melt was either added drop-wise or injected into
excess water, with continuous stirring on a magnetic stirrer
such that the concentration of lipid in the sample was approx-
imately 8–10% (w/w). The final volume was made up to
100.0 mL with distilled water (Table I). The samples were
allowed to equilibrate at room temperature overnight. The
samples were then homogenized for 2 min in a homogenizer
at 1500–2000 rpm.
Preparation of Gelling System
Poloxamer solutions were prepared according to the
Bcold method^ previously described by Soga et al. with
some modifications (33). Briefly, Pluronic® F127 and
Pluronic® F68 were accurately weighed and solubilized in
required volume of distilled water by continuous stirring,
along with the addition of HPMC K4M. The dispersion
was left to hydrate overnight (4–8°C) to obtain a uniform,
glassy solution. After complete hydration of the polymers,
the resultant solution was thoroughly mixed on a magnetic
stirrer until a uniform and clear solution was obtained.
The composition of different gelling systems prepared is
shown in Table II.
Preparation of Thermoresponsive Depot System
Cubosome-containing thermoresponsive depot system
was prepared by incorporation of previously prepared
cubosome dispersion into the poloxamer gelling system.
Final formulation was prepared by addition of cubosome
dispersion (20 mg/mL) into the gelling system in the ratio of
1:2. The solution was then continuously stirred on a mag-
netic stirrer at 25°C for 24 h to get a homogenous mixture.
The composition of different formulations prepared is
shown in Table III.
Drug-Excipient Compatibility Studies
Thermal Analysis
The drug, the polymers, and their physical mixtures
with DTX were analyzed by differential scanning calorim-
etry (DSC). Open pan DSC measurements were carried
out using a DSC Q20 (TA Instruments Inc., New Castle,
DE) with a sample size of approximately 5 mg weighed
into each aluminum pans. Samples were heated at 10°C/
min from 0 to 400°C. Nitrogen at a flow rate of 40 mL/
min was used as a purge gas in DSC analyses. The results
were analyzed using the Universal Analysis software ver-
sion 4.5A, build 4.5.0.5 (TA Instruments, Inc., New Castle,
DE, USA).
FTIR Spectroscopy
To determine any possible interactions, the physical
mixtures of the drug and the polymers were analyzed
using the Fourier transformed infrared (FTIR) spectrosco-
py. Briefly, the samples were dried in a hot air oven at
50°C for 2 h. The samples were compressed under pres-
sure of 10 t/nm2 to prepare circular KBr disks. The sam-
ples were scanned in the range of 400 to 4000 cm−1. The
shifts in the spectra of the drug in the presence of poly-
mers and other components were investigated to deter-
mine physical interactions between the drug and the
polymers, if any.
Characterization of Cubosomes
Particle Size and Zeta Potential Analysis
The particle size analysis of the blank and the DTX-
loaded cubosomes was carried out using photon correlation
spectroscopy (PCS), with dynamic light scattering on a
Zetasizer® nano (Model: Zen 3600, Malvern Instruments,
Malvern, UK) equipped with a 5-mW helium neon laser with
a wavelength output of 633 nm. The measurements were
carried out at 25°C, at an angle of 90°, and a run time of at
least 40–80 s. Water was used as a dispersant. The zeta poten-
tial was measured by Smoluchowski’s equation from the elec-
trophoretic mobility of cubosomes (34). All measurements
were performed in triplicate.
Table I. Formulation of Cubosome Dispersion Using Pluronic® F127
Cubosome dispersion
formulation
Glyceryl monooleate
(% w/w)
Pluronic F127
(% w/w)
Ethanol DTX (% w/v) Distilled water
CD 1 9 1 5 mL – q.s*
CD 2 9 1 5 mL 2 q.s
*q.s. quantity sufficient to make 100 mL
Table II. Composition of the Thermoresponsive Gelling Systems
Gelling
system
Pluronic®
F127
(% w/v)
Pluronic®
F68
(% w/v)
HPMC
K4 M
(% w/v)
Distilled
water
G1 18 18 0.5 q.s.*
G2 19 18 0.5 q.s.
G3 20 18 0.5 q.s.
G4 18 19 0.5 q.s.
G5 19 19 0.5 q.s.
G6 20 19 0.5 q.s.
G7 20 20 0.5 q.s.
G8 18 35 0.5 q.s.
G9 18 38 0.5 q.s.
G10 18 40 0.5 q.s.
G11 17 35 0.5 q.s.
G12 17 38 0.5 q.s.
*q.s. quantity sufficient to make 100 mL
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Entrapment Efficiency
The entrapment efficiency i.e., the DTX content en-
capsulated in cubosomes, was evaluated using a combina-
tion of methods described previously in the literature (35–
37). Briefly, 1 mL of cubosomes containing DTX were
added into the reservoir of Centricon® (Model: YM-100,
Amicon, Millipore, Bedford, MA, USA). After centrifug-
ing the cubosome dispersion at 15,000 rpm for 40 min, the
filtrate containing free DTX was removed. The filtered
dispersion was then diluted with methanol and analyzed
for DTX content using HPLC. The HPLC analysis was
used to compute the total concentration of DTX (Ct), and
the concentration of DTX contained in the filtrate after
centrifugation (Cf). The entrapment efficiency was calcu-
lated using the following equation:
Entrapment efficiency %ð Þ ¼ Ct−Cf
Ct
 
 100
Determination of In-Vitro DTX Release from Cubosomes
The DTX release from the cubosome dispersion was
evaluated by measuring the diffusion of the drug across a
cellophane membrane using Franz diffusion cell. The cell
consisted of two compartments i.e., the donor compart-
ment and the receptor compartment. A previously activat-
ed semipermeable membrane was placed between these
two compartments. The dispersion formulation was added
on to the donor compartment above the membrane. The
receptor compartment contained 18 mL phosphate buffer
saline solution (PBS, pH 7.4), maintained at 37±0.5°C, as
a release medium. At predetermined time intervals, ali-
quots of the release medium were withdrawn and replaced
with an equal volume of fresh release medium. The drug
concentrations in the release medium at various time in-
tervals were analyzed using HPLC.
HPLC Analysis of DTX
DTX concentration was measured using HPLC analysis
(SPD-10Avp Shimadzu pump, LC-10Avp Shimadzu UV-vis
detector) at 230 nm as previously described by Loos et al.
(38). Briefly, samples were chromatographed on a
4.6 mm×250 mm reverse phase stainless steel column packed
with 5 μm particles (Venusil XBP C-18, Agela, China) and
eluted with a mobile phase consisting of acetonitrile/water
(55:45, v/v) at a flow rate of 1 mL/min. The column tempera-
ture was maintained at room temperature. The samples were
appropriately diluted with methanol and injected (20 μL) di-
rectly into the HPLC system without further treatment. The
calibration of the peak area against concentration of DTX was
found to be y=11485x−647.64 with r2=0.9998 for the DTX
concentration range of 1–40 μg/mL (where y: peak area and
x: DTX concentration), and the limit of detection was found to
be 0.02 μg/mL.
Characterization of Gelling System
Determination of Gelation Temperature by Tilting Method
The gelation temperature was determined using the
method described earlier by Zaki et al. (39). Briefly, 2 mL
aliquots of the polymer solution were transferred to a test tube
and immersed in the water bath. The temperature of the water
bath was increased slowly and allowed to equilibrate for 5 min
at each new setting. The sample was then examined for gela-
tion, which was said to have occurred when the meniscus
would no longer move upon tilting at a 90° angle. Thermore-
versible polymer-based liquid formulations, which provide in-
situ gelling property at physiological temperatures, were de-
veloped with a goal of delaying the release of DTX from the
depot system.
Determination of pH of the Gelling System
The pH of each formulation was determined by using a
pH meter (Model: S220 SevenCompact™ pH/Ion, Mettler
Toledo, USA). The pH meter was first calibrated using stan-
dard solutions of pH 4 and pH 9.2. The commonly observed
pH range for in-situ gel formulations is 6.0–7.5 (40–43).
Characterization of Thermoresponsive Depot System
Determination of Gelation Time
The gelation time was determined by increasing the tem-
perature of the formulations up to 37°C, and the time required
by the formulations (containing different concentrations of the
polymers) to form a stiff gel was recorded using a digital
stopwatch.
In-Vitro Gel Erosion Study
The vials (inner diameter=13.5 mm) containing approxi-
mately 1 g of prepared solution were placed in a water bath,
maintained at a constant temperature of 37°C. After the for-
mulations had transformed into gels, 1.5 mL PBS (pH 7.4),
pre-warmed to 37°C, was carefully layered over the gel sur-
face. At predetermined intervals, the entire release medium
was removed, and the weight of the vial and the remaining gel
was recorded. The percentage weight loss of the gel was
calculated by dividing the decrease in the weight of the gel
by the initial gel weight.
Table III. Thermoresponsive Depot Systems Containing DTX-
Loaded Cubosomes
Formulation Gelling
systema
Cubosome
dispersion (mL)
Cubosome:
gelling system
PF127 PF68
F1 19% 18% 2 1:2
F2 20% 18% 2 1:2
F3 20% 20% 2 1:2
F4 20% 19% 2 1:2
F5 19% 19% 2 1:2
F6 18% 19% 2 1:2
PF127 Pluronic® F127, PF68 Pluronic® F68
aQuantities indicate the % w/v composition of PF127 and PF68
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Gel Formation and Injectability Test
The injectability test of the prepared formulations was
carried out using a 22-gauge needle and a syringe which is
generally used for intramuscular administrations. Accurately
measured formulation (2 mL) was injected into the release
media (PBS, pH 7.4) maintained at a constant temperature of
37°C, and the ease of injection of the formulations through the
needle was visually observed.
In-Vitro DTX Release Study from Depot Formulation
The Binverted cup^ method, as described by Soderberg
et al., was used with some modifications, to study the drug
release from the depot formulations (44). Briefly, the formu-
lation was introduced in an inverted cup, through a hole, by
the means of a 1-mL syringe. The flow of the release medium
around the sample was controlled by the stirring rate of the
magnetic bar. The speed of the magnetic stirrer was main-
tained at 200 rpm. One thousand milliliters of PBS (pH 7.4)
was used as a standard release medium, which filled the con-
ical flask to the rim. The temperature of the system was
maintained at 37±0.5°C. One-milliliter samples of the release
medium were drawn at hourly intervals up to 12 h. All the
tests were performed in triplicate. The drug concentrations in
the release medium were measured using HPLC analysis, as
described above.
Statistical Analysis
All data were expressed as mean±standard deviation
(SD). The statistical analysis was carried out by a two-way
analysis of variance (ANOVA) followed by Bonferroni post-
test using GraphPad® Prism® software version 5.03 (San
Diego, CA). The differences between means were considered
to be significant if the P value was <0.05.
RESULTS
Drug-Excipient Compatibility Studies
Thermal Analysis
The DSC thermogram of pure DTX showed a sharp
endothermic peak at ∼169°C, corresponding to DTX melting
point (thermograms not shown). Additionally, the DSC ther-
mograms of Pluronic® F127 and Pluronic® F68 revealed sharp
endothermic peaks at temperatures of∼58 and ∼56°C, respec-
tively. HPMC K4M revealed broad, undefined endothermic
peak over a temperature range of 20–80°C. Such broad endo-
thermic peaks, mainly due to the dehydration process, are
typically observed with predominantly amorphous polymers.
The DSC analysis of the physical mixtures, DTX:
Pluronic® F127 (1:1), DTX: Pluronic® F68 (1:1), and DTX:
HPMC K4M (1:1), revealed a negligible and a non-significant
change in the thermal behavior of DTX in the presence of
these polymers. Additionally, the melting signals (endotherm)
of Pluronic® F127, and Pluronic® F68 were clearly distinguish-
able in the physical mixtures of the respective polymers with
DTX. The absence of any other endothermic/exothermic
event over the entire temperature range thus excluded any
physical interaction or obvious incompatibility between the
drug and the polymers. The DSC results thus indicated the
suitability of these polymers to be used in the prepared
formulations.
Fourier Transform Infrared (FTIR) Spectroscopy
The FTIR spectra for DTX, Pluronic® F127, Pluronic®
F68 and HPMC K4M individually, the binary mixtures of the
drug with individual polymers, as well as a mixture of the drug
with all the polymers, are shown in Fig. 2. The FTIR analysis
did not show any significant difference between the individual
spectra and those obtained from their physical mixtures. The
results obtained after the FTIR study thus indicated that there
was no positive evidence for the interaction between docetax-
el trihydrate and the used polymers.
Characterization of Cubosome
Particle Size Determination
Smaller particles have higher surface area/volume ratio,
which makes it easier for the encapsulated drug to be released
from the cubosome via diffusion and surface erosion, and also
have the added advantage for the drug-loaded cubosomes to
penetrate into and permeate through the physiological drug
barriers. It has been previously suggested that the larger par-
ticles (<5 mm) would be taken up via the lymphatics, and the
smaller particles (<500 nm) can cross the membrane of epi-
thelial cells through endocytosis (45,46). The mean particle
size, polydispersity index (PDI), and the zeta potential values
of cubosome dispersion prepared by Pluronic® F127, with
(CD2) and without DTX (CD1), are shown in Table IV. The
mean particle size of blank cubosomes (CD1) and DTX-
loaded cubosomes (CD2) were found to be 184.9±2.47 and
220.9±3.02 nm, respectively. Thus, the DTX loading was found
to only marginally increase the mean particle size of the
cubosomes. Moreover, the low polydispersity index values,
0.162±0.014 and 0.173±0.019 for blank cubosomes (CD1)
and DTX-loaded cubosomes (CD2), respectively, indicated a
narrow particle size distribution (47). Zeta potential is another
important index for the stability of the cubosomes. A high
absolute value of zeta potential indicates a high electric charge
on the surface of the cubosomes, which can cause strong
repellent forces among particles and prevent aggregation of
the cubosomes in a buffer solution (37,48). The zeta potential
of blank cubosomes (CD1) and DTX-loaded cubosomes
(CD2) were found to be −54.1±1.57 and−47.4±1.80 mV, re-
spectively. Typically, a minimum zeta potential of greater than
−30 mV is considered acceptable and indicative of a good
physical stability (49).
Entrapment Efficiency
The drug entrapment efficiency is an important parame-
ter for drug delivery systems. This is especially true for expen-
sive drugs. The entrapment efficiency of the docetaxel-loaded
cubosomes was found to be 94.74±3.41 (% w/w), indicating
that most of DTX was encapsulated in cubosomes.
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Table IV. Particle Size, Polydispersity Index, and Zeta Potential of Cubosomes Prepared with Pluronic F127
Cubosome dispersion formulation Particle size (nm) Polydispersity index (PDI) Zeta potential (mV)
CD 1 184.9±2.47 0.162±0.014 −54.1±1.57
CD 2 220.9±3.02 0.173±0.019 −47.4±1.80
Values are mean±std. dev. (n=3)
Fig. 2. FTIR analysis of the drug and the polymers. a Docetaxel trihydrate, b Pluronic® F127, c Pluronic® F68, d HPMC K4M, e docetaxel
trihydrate: Pluronic® F127 (50:50), f docetaxel trihydrate: Pluronic® F68 (50:50), g docetaxel trihydrate: HPMC K4M (50:50), h docetaxel
trihydrate: Pluronic® F127: Pluronic® F68: HPMC K4M (25:25:25:25)
441Nanostructured Cubosomes in a Thermoresponsive Depot System
In-Vitro DTX Release from Cubosome Dispersion
Figure 3 shows the release pattern of DTX from the
cubosome dispersion (CD2) as evaluated using the Franz
diffusion cell. The drug-loaded cubosomes exhibited an initial
burst release (32.49%) within 1 h. This was followed by a
controlled release of DTX from the cubosomes over a period
of 12 h. At the end of 12 h, over 95% of DTX was released
from the cubosomes. The results indicated the potential of
cubosomes to be utilized in the controlled drug delivery
systems.
Characterization of Gelling System
The pH of all tested formulations was found to be in the
range of pH 6.5–7.5.
Determination of Gelation Temperature by Tilting Method
The sol-to-gel transition end-point was determined by the
Btilting method^ (Fig. 4). The gelation temperature of the
thermoresponsive gelling systems containing different ratios
of the polymers were found to be in the range of 29–40°C.
Specifically, the gelation temperature for the formulation F2
containing Pluronic® F127 (20%), Pluronic® F68 (18%), and
HPMC K4M (0.5%) was found to be in the range of 36–38°C,
which is considered appropriate for the in-situ gelling of the
system (26,31,33,50–52).
Characterization of Thermoresponsive Depot System
Determination of Gelation Time
The time required by the prepared thermoresponsive
depot formulations to form a stiff gel (sol-to-gel transition)
in response to increasing temperature is listed in Table V. The
temperature was increased from 10 to 37°C at the rate of 2°C/
min. The temperature was then maintained at 37±0.5°C, and
the lag time of gelation for each formulation was determined.
The formulations exhibited a wide range of gelation lag times.
The formulation F2 was found to gel rapidly and demonstrat-
ed the shortest lag time of 3 min and 5 s.
In-Vitro Gel Erosion Study
The erosion of the gel from the prepared formulations
was calculated by determining the gel loss (% w/w) at various
time intervals, after the gel-containing vials were allowed to
incubate at 37±0.5°C. Table VI summarizes the rates of gel
erosion (% w/w) at various time intervals. The formulations
F1, F2, F3, F4, F5, and F6 exhibited 46.3%, 39.0%, 38.1%,
38.3%, 39.4%, and 41.0%, respectively, after 96 h. The extent
of erosion was not found to be statistically significant between
the formulations.
Gel Injectability Test
The parenteral administration of DTX requires passage
of formulation through the needle for easy injectability. The
injectability test carried out for prepared depot formulation
showed that all the formulations successfully passed through a
22-gauge needle.
In-Vitro DTX Release Study from Thermoresponsive Depot
Formulation
The cubosome dispersion-based depot formulations of
DTX were injectable solutions at room temperature and
turned into stiff gels rapidly at 37°C. The results from the in-
vitro drug-release study are shown in Fig. 3. The release of
DTX from cubosomes over a period of 12 h is compared with
the DTX release from the depot formulations containing
DTX-loaded cubosomes. The cubosomes exhibited a non-lin-
ear, albeit sustained release of DTX over a period of 12 h. At
the end of 12 h, over 95% of DTX was released from the
cubosomes. The formulation F2 showed an initial burst re-
lease of 21.48±1.59%, followed by a controlled release of
DTX for over 12 h. Formulations F3 and F5 showed initial
burst release of 21.06±1.67 and 20.77±1.64%, respectively, and
controlled the DTX release over 12 h. Whereas, formulation
F1, F4, and F6 exhibited an initial burst release to 16.12
±1.04%, 16.80±1.07%, and 15.63±0.98%, respectively, and
prolonged the release of DTX for over 12 h. At the end of
12 h, the DTX release ranged from 39 to 60% from these
formulations.
Fig. 3. The in-vitro release of DTX from cubosomes and from
thermoresponsive depot formulations. All values are mean±SD (n=3).
*p<0.01, compared to DTX-loaded cubosomes
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DISCUSSION
A docetaxel-loaded thermoresponsive depot system for a
controlled release was prepared. This depot system was eval-
uated for various parameters like gelation time, injectability,
gel erosion (%), and in-vitro drug release. Formulations con-
taining different concentrations of PF127 (18–20% w/v) were
found to flow freely at ambient room temperature. The for-
mulations containing a lower concentration of Pluronic® F127
(18% w/v) exhibited a higher gelation temperature, as deter-
mined by the test tube Btilting^ method. On the other hand, the
formulations containing a higher concentration of Pluronic®
F127 (20% w/v) were observed to form a stable gel at lower
temperature. The concentration of Pluronic® F68 was also
found to have a significant effect on the gelation temperature
of the gelling system. The formulations containing 18 or 19%
w/v Pluronic® F68 demonstrated lower gelation temperatures
compared to those containing 20–19% of Pluronic® F68.
In contrast to results obtained in this study, Wei et al.
reported that addition of pluronic® F68 into Pluronic® F127
based thermoresponsive gels decreases sol-gel transition tem-
perature (52). Vadnere et al. had previously demonstrated that
this was due to higher hydrophilicity of the Pluronic® F68 than
that of the Pluronic® F127, which could disrupt the hydration
shells around the hydrophobic portion of Pluronic® F127 mol-
ecules (51). Klouda et al. also explained the changes in prop-
erties of Pluronic® F127 molecule after a change in
concentration and temperature of the Pluronic® solution sys-
tem (50). This was the main reason for selecting the concen-
trations of Pluronic® F127 (20% w/v) and Pluronic® F68 (18%
w/v) for further study and formulation of the depot system.
The depot formulation showed a rapid sol-to-gel transition at
temperatures close to physiological temperature i.e., 37
±0.5°C. The prepared formulations showed a range of lag time
for gelation. Among the formulations tested, the formulation
containing 20% of Pluronic® F127 and 18% of Pluronic® F68
exhibited the fastest sol-to-gel transition i.e., a lower lag time
of 3 min 5 s. The results of injectability test carried out for
prepared depot formulation showed that the formulations
were able to pass easily from a 22-gauge needle. The in-vitro
gel erosion study showed that the formulation containing 20%
Pluronic® F127 and 18% Pluronic® F68 had a relatively higher
gel strength (only 39.0% of gel erosion after 96 h). The for-
mulations containing lower concentration of Pluronic® F127
(19%) and Pluronic® F68 (18%) exhibited lower gel strength
(46.3% gel erosion after 96 h). The results indicate that the gel
strength of the system enhances when the concentration of
Pluronic® F127 was gradually increased, along with the addi-
tion of 0.5% HPMC K4M which act as a gelling agent and
tends to improve the gel strength. The concentration of
HPMC K4M was chosen by studying the effect of various
concentrations of HPMC K4M (0.3–1.0%) on the gel behav-
ior, gel erosion, and gel stability in aqueous environment. The
concentration of HPMCK4Mwhen increase from 0.3 to 1.0%,
the stability and gel strength were also found to be increased.
However, the gelling system containing 1.0% HPMC K4M
resulted in a turbid formulation, while that containing 0.3%
HPMC K4M showed the formation of a transparent glassy
solution with lower gel strength. Thus, a concentration of
0.5% HPMC K4M was found to be optimal for the prepared
thermoresponsive formulations; this concentration resulted in
a gel with sufficient gel strength without any noticeable
turbidity.
The in-vitro drug release studies on cubosome disper-
sions, carried out using the Franz diffusion cell, revealed that
loading of DTX into cubosome considerably slowed the re-
lease of DTX, extending up to 12 h. Further reduction of
release was observed from the drug-loaded cubosomes, when
incorporated into the thermoresponsive depot system. The
prepared thermoresponsive depot formulation exhibited a
controlled release of the drug compared to the drug release
from cubosome dispersion alone. These findings were expect-
ed, and can be attributed to an increase in the number of
barriers to the passive diffusion of the drug. The drug loaded
in cubosomes has to cross only one barrier of cubosome.
However, when incorporated into a thermoresponsive gelling
system, cubosomes act as a drug-reservoir surrounded by a
protective layer of gelling system which enabled drug release
over a prolonged time, i.e., over 12 h. The formulation of
thermoresponsive depot system containing cubosomes and
the gelling system (prepared using a combination of Pluronic®
F127 (20%) and Pluronic® F68 (18%)) showed an initial burst
release (21.48±1.59%) within the first hour and extended the
Table V. The Sol-To-Gel Lag Time for Different Formulations
Formulation Sol-to-gel lag timea (min)
F1 3.50±0.12
F2 3.05±0.13
F3 10.25±0.46
F4 20.48±0.94
F5 18.05±0.87
F6 18.20±0.82
Values are mean±std. dev. (n=3)
aAll values are measured at 37±0.5°C
Fig. 4. Sol-to-gel transition of the dispersion. a Dispersion at 10°C and b dispersion at the
gelation temperature (36–38°C)
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release of of DTX over 12 h. Only 39.83±3.27% of the drug
was found to be released from this formulation at the end of
12 h. The results thus indicate the feasibility of the formula-
tions based on cubosome-thermoresponsive gel system, as a
promising delivery system for controlled release of docetaxel
and similar drugs.
CONCLUSIONS
A simple process, based on the dispersion and homoge-
nization of glyceryl monooleate and Pluronic® in water, leads
to the formulation of cubosomes. The incorporation of the
drug-loaded cubosomes into a thermoresponsive gelling sys-
tem resulted in a slower and a prolonged drug release. Ac-
cording to the results of this study, a thermoresponsive depot
system based on Pluronic® (F127 and F68), containing
cubosomal DTX, can be developed for a controlled drug
delivery.
The cubosome-containing thermoresponsive depot
formulation was found to be free flowing at ambient
temperature and formed a depot gel at body temperature.
Cubosomes may not only provide the means for substan-
tially increased lipophilic drug loading but it may also act
as a reservoir for sustained drug release. Therefore, this
system containing the drug-loaded cubosomes incorporat-
ed in a thermoresponsive gelling system can be effectively
used as controlled-release depot formulations. Neverthe-
less, further specialized studies such as detailed microscop-
ic characterization of cubosome formation, as well as the
drug loading in cubosomes, are required to further our
understanding of this system as an alternative, parenteral-
controlled drug delivery system.
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